ALNY up +1.29% percent right now. $ALNY High is at 100.48 and the Low 97.55 with current volume of 205,610.
Recent News posted below.
ALNY Alnylam Pharmaceuticals Recent Headline News
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 99.05 (-0.13)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 99.05 (-0.13)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 99.05 (-0.13)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 24.09 (-1.82), BXE: 4.62 (+0.04), ROKA: 3.50 (-0.08), ALNY: 99.05 (-0.13), NCT: 4.86 (+0.12), SSRI: 4.93 (+0.19), ABCB: 25.95 (+0.40), OSIR: 13.43 (-0.05), XCO: 3.24 (+0.06), JDST: 23.40 (-5.65)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.09 (-3.78), ALNY: 99.05 (-0.13), ISIS: 51.04 (+3.81), OGXI: 2.15 (+0.02), TEVA: 58.18 (+0.14), RGLS: 20.32 (-0.59), GSK: 45.80 (+0.64), SNY: 46.99 (+0.80)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 99.05 (-0.13), MDCO: 24.29 (-0.07), SNY: 46.99 (+0.80)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 99.05 (-0.13)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.09 (-3.78), ALNY: 99.05 (-0.13), AMAG: 34.87 (-0.04)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:12PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.05 (-0.13), AMGN: 162.74 (-0.35), SNY: 46.99 (+0.80), REGN: 396.90 (+10.93)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals (ALNY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:19PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress
Business Wire - Wed Nov 05, 3:00PM CST
--- Completed Phase 2 Enrollment and Initiated Phase 2 OLE Study with Revusiran (ALN-TTRsc), and Successfully Completed Non-Clinical Chronic Toxicology Studies to Enable Start of Phase 3 Trial -
ALNY: 99.05 (-0.13)
Alnylam completes enrollment in cardiac amyloidosis trial
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 11:52AM CST
ALNY: 99.05 (-0.13)
Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Wed Nov 05, 7:01AM CST
--- On Track to Initiate Phase 3 Trial by Year End Following Successful Completion of Regulatory Discussions in U.S. and EU -
ALNY: 99.05 (-0.13)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST
CXO: 116.56 (+0.98), CODI: 16.91 (-1.39), EXXI: 7.10 (+0.08), JCOM: 55.89 (+0.14), ATSG: 8.49 (-0.16), GPOR: 53.80 (+0.33), ENS: 60.08 (-0.19), ECYT: 6.52 (+0.34), ALNY: 99.05 (-0.13), KGC: 2.43 (+0.09), GSM: 18.51 (-0.20), BKD: 32.89 (-0.19), DK: 31.01 (-0.17), AR: 55.10 (+0.32), IL: 9.48 (+0.39), DVR: 0.14 (-0.08), IO: 2.96 (+0.23), DEPO: 14.51 (-0.04), ETE: 61.75 (-0.23), AVG: 19.35 (-0.24), CSOD: 28.85 (+0.08), GNW: 8.35 (+0.23), ECOL: 44.16 (+0.14), BWC: 30.10 (-0.30), CPE: 6.13 (+0.07), FNV: 51.02 (+3.16), CTL: 39.93 (+0.09), ASH: 112.59 (+0.91), ENSG: 40.37 (-0.26), CLR: 54.75 (+0.53), ACAS: 15.55 (+0.04), G: 17.92 (-0.01), BREW: 13.60 (-0.23), AWK: 52.57 (-0.30), CVG: 21.25 (-0.21), AREX: 10.94 (+0.33), HTCH: 3.70 (unch), ETP: 64.61 (-0.76), ABTL: 10.66 (-0.03), FMI: 24.97 (+0.26), DPM: 51.46 (-0.81), BCOR: 14.55 (-0.15), CDE: 3.83 (+0.25), DRYS: 1.41 (-0.06), KW: 27.82 (-0.08), BALT: 3.26 (-0.01), ATO: 54.11 (-0.19), EXAR: 8.83 (+0.24), ACLS: 2.16 (+0.01), INWK: 7.56 (-0.08), ALSK: 1.35 (-0.10), CF: 265.88 (+11.48), EFC: 21.83 (-0.14), BIOS: 5.72 (+0.13), DYN: 34.30 (-0.19), DATA: 84.27 (+0.72), ANDE: 54.29 (-0.48), HOLX: 26.53 (-0.02), CBS: 51.86 (-0.27)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.98 (-0.97), ACT: 241.91 (-3.82), PRGO: 155.44 (-1.12), ALNY: 99.05 (-0.13)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.66 (-0.04), MDVN: 107.98 (-0.97), ALNY: 99.05 (-0.13), HUM: 135.02 (+2.56)
Recent News posted below.
ALNY Alnylam Pharmaceuticals Recent Headline News
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
Business Wire - Tue Nov 11, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline. Specifically, in a presentation at the American Association for the Study of Liver Diseases (AASLD) meeting, the company announced it has added ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. Further, it has added ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections. In addition, Alnylam continues to advance its ALN-HBV program, in development for the treatment of hepatitis B viral (HBV) infection; the company remains on track to select a Development Candidate (DC) by the end of the year and expects to file an investigational new drug (IND) application or IND equivalent around the end of 2015.
ALNY: 99.05 (-0.13)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 3.48% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:33PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $95.84 to a high of $99.87. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $97.19 on volume of 715,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 99.05 (-0.13)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 61.6% (ALNY)
Comtex SmarTrend(R) - Mon Nov 10, 12:24PM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 61.63% as of today's recent price of $99.17.
ALNY: 99.05 (-0.13)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 24.09 (-1.82), BXE: 4.62 (+0.04), ROKA: 3.50 (-0.08), ALNY: 99.05 (-0.13), NCT: 4.86 (+0.12), SSRI: 4.93 (+0.19), ABCB: 25.95 (+0.40), OSIR: 13.43 (-0.05), XCO: 3.24 (+0.06), JDST: 23.40 (-5.65)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.09 (-3.78), ALNY: 99.05 (-0.13), ISIS: 51.04 (+3.81), OGXI: 2.15 (+0.02), TEVA: 58.18 (+0.14), RGLS: 20.32 (-0.59), GSK: 45.80 (+0.64), SNY: 46.99 (+0.80)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 99.05 (-0.13), MDCO: 24.29 (-0.07), SNY: 46.99 (+0.80)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 99.05 (-0.13)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.09 (-3.78), ALNY: 99.05 (-0.13), AMAG: 34.87 (-0.04)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:12PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.05 (-0.13), AMGN: 162.74 (-0.35), SNY: 46.99 (+0.80), REGN: 396.90 (+10.93)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals (ALNY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:19PM CST
ALNY: 99.05 (-0.13)
Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress
Business Wire - Wed Nov 05, 3:00PM CST
--- Completed Phase 2 Enrollment and Initiated Phase 2 OLE Study with Revusiran (ALN-TTRsc), and Successfully Completed Non-Clinical Chronic Toxicology Studies to Enable Start of Phase 3 Trial -
ALNY: 99.05 (-0.13)
Alnylam completes enrollment in cardiac amyloidosis trial
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 11:52AM CST
ALNY: 99.05 (-0.13)
Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Wed Nov 05, 7:01AM CST
--- On Track to Initiate Phase 3 Trial by Year End Following Successful Completion of Regulatory Discussions in U.S. and EU -
ALNY: 99.05 (-0.13)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST
CXO: 116.56 (+0.98), CODI: 16.91 (-1.39), EXXI: 7.10 (+0.08), JCOM: 55.89 (+0.14), ATSG: 8.49 (-0.16), GPOR: 53.80 (+0.33), ENS: 60.08 (-0.19), ECYT: 6.52 (+0.34), ALNY: 99.05 (-0.13), KGC: 2.43 (+0.09), GSM: 18.51 (-0.20), BKD: 32.89 (-0.19), DK: 31.01 (-0.17), AR: 55.10 (+0.32), IL: 9.48 (+0.39), DVR: 0.14 (-0.08), IO: 2.96 (+0.23), DEPO: 14.51 (-0.04), ETE: 61.75 (-0.23), AVG: 19.35 (-0.24), CSOD: 28.85 (+0.08), GNW: 8.35 (+0.23), ECOL: 44.16 (+0.14), BWC: 30.10 (-0.30), CPE: 6.13 (+0.07), FNV: 51.02 (+3.16), CTL: 39.93 (+0.09), ASH: 112.59 (+0.91), ENSG: 40.37 (-0.26), CLR: 54.75 (+0.53), ACAS: 15.55 (+0.04), G: 17.92 (-0.01), BREW: 13.60 (-0.23), AWK: 52.57 (-0.30), CVG: 21.25 (-0.21), AREX: 10.94 (+0.33), HTCH: 3.70 (unch), ETP: 64.61 (-0.76), ABTL: 10.66 (-0.03), FMI: 24.97 (+0.26), DPM: 51.46 (-0.81), BCOR: 14.55 (-0.15), CDE: 3.83 (+0.25), DRYS: 1.41 (-0.06), KW: 27.82 (-0.08), BALT: 3.26 (-0.01), ATO: 54.11 (-0.19), EXAR: 8.83 (+0.24), ACLS: 2.16 (+0.01), INWK: 7.56 (-0.08), ALSK: 1.35 (-0.10), CF: 265.88 (+11.48), EFC: 21.83 (-0.14), BIOS: 5.72 (+0.13), DYN: 34.30 (-0.19), DATA: 84.27 (+0.72), ANDE: 54.29 (-0.48), HOLX: 26.53 (-0.02), CBS: 51.86 (-0.27)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.98 (-0.97), ACT: 241.91 (-3.82), PRGO: 155.44 (-1.12), ALNY: 99.05 (-0.13)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.66 (-0.04), MDVN: 107.98 (-0.97), ALNY: 99.05 (-0.13), HUM: 135.02 (+2.56)
